Background: Interleukin (IL)-17 is a key molecule for epithelial immunity and inflammation. Objectives: To quantify IL-17 expression in situ in a large panel of cutaneous diseases. Materials & Methods: 289 samples of the 30 most common cutaneous infectious, autoimmune, inflammatory and tumor diseases were stained for IL-17 immunohistochemically. Results: IL-17 expression strongly varied between the diseases, but was conserved within each disease. The major cellular sources of IL-17 were T cells and granulocytes. Skin diseases caused by extracellular microbials were infiltrated by many IL-17+ cells, while intracellular infections were scarcely positive for IL-17. While autoimmune diseases were mostly accompanied by IL-17+ T cells, IL-17+ granulocytes were dominant in neutrophilic dermatoses. Conclusion: Cutaneous diseases show a characteristic pattern of IL-17+ cellular infiltrate. These patterns are relevant for the clinician, since therapeutic approaches targeting differentiation of Th17 cells as well as direct targeting of IL-17 are or will become available.
I
nterleukin-17A/F belong to the class of "tissuesignaling cytokines" that are immune cell-derived cytokines with major impact on epithelial tissue [1] . Since its discovery in 1993 by Rouvier and colleagues [2] , there is an enormous scientific interest in the source and functional impact of IL-17. Today, we know that IL-17A/F are produced mainly by Th17 cells, but also by other T helper cells such as IFN-␥ producing Th1 or IL-4 producing Th2 cells as well as by innate immune cells like NK cells, follicular helper cells or neutrophil granulocytes [1, 3] . Concerning the function, IL-17 is a key cytokine for epithelial immunity [1, 4] . Loss of IL-17 results in selective chronic infections of the skin and mucosal membranes with fungi and/or bacteria [5] . An ineffective IL-17 signaling is also reported in atopic eczema due to counteracting Th2 cytokines [6] . In patients with co-existing psoriasis and atopic eczema, skin colonization with extracellular microbials is limited to the sites of eczema, where the Th2/IL-17 ratio is increased as compared to psoriasis [7] . Beyond innate immunity, IL-17 acts synergistically with IFN-␥ to induce adhesion molecules such as ICAM-1 or MHC antigens on keratinocytes [8] . This results in an increased unspecific T cell mediated cytotoxicity that is a critical hallmark in many inflammatory skin diseases, but also in tumor homeostasis. However, in contrast to cellular sources and functional aspects of IL-17 in vitro, little is known about the in situ expression of IL-17 in cutaneous pathologies.
Materials and Methods
289 samples of the 30 most common inflammatory, infectious, auto-immune and tumor diseases in the skin were stained for IL-17. Diagnoses were made in the routine histological department and sections were stained for IL-17 as published previously [8, 9] . Briefly, paraffin-embedded sections were incubated in a pH 6 epitope retrieval solution (Dako), and subsequently incubated with goat anti-human IL-17 (R&D systems), a biotinylated anti-goat secondary antibody (Vector), Streptavidin peroxidase, and the substrate 3-amino-9-ethyl-carbazole (Dako). Finally, slides were counterstained with hematoxylin. Infiltrating immune cells were counted manually in two visual fields for each sample in a blinded manner. Infiltrating cells were grouped morphologically into mononuclear and polymorphic nuclear cells, and the absolute and relative number of IL-17+ cells was determined.
Results
The relative and absolute number of IL-17+ cells was highly heterogeneous among different skin diseases, but a similar pattern was observed within each disease. Besides T cells, a second major population of IL-17+ cells displayed a polymorphic nucleus and consisted of both eosinophil and neutrophil granulocytes. Among infectious diseases, a few cells stained positive for IL-17 in viral diseases such as verruca vulgaris or condyloma acuminatum ( figure 1,  table 1 ). In contrast, bacterial and fungal infections such as abscesses and tinea, respectively, were highly positive for IL-17+ lymphocytes and granulocytes. Granulomatous and fibrotic autoimmune and infectious diseases such as acrodermatitis chronica atrophicans, morphea, lichen sclerosus et atrophicus, granuloma anulare and sarcoidosis were dominated by IL-17+ lymphocytes with few IL-17+ neutrophils. In contrast, in the bullous autoimmune diseases • 
Discussion
In summary, the quantity of IL-17+ cells in cutaneous diseases is highly heterogeneous and disease-specific. These results are of clinical interest, since they give information as to where biological agents interfering with IL-17 are promising (table 1) . A good clinical outcome with anti-IL12p40 antibodies (Ustekinumab, Briakinumab), that mostly target T cells, may be expected in diseases with a high number of IL-17+ lymphocytes, such as fibrotic and granulomatous diseases. Ustekinumab has also been reported to be efficient in two cases of pyoderma gangraenosum [10, 11] . However, the results reported here suggest that cutaneous diseases associated with many IL-17+ granulocytes could benefit even more from direct targeting of the IL-17 signaling with anti-IL-17 (AIN457, LY2439821).
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